Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Matthew Burke Discusses Adverse Events

      March 5, 2014
      By Matthew Burke, MBA, RN, MSN, APRN-BC
      Article

      Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

      Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

      Burke says chemotherapy-related adverse events are usually limited to the time that the drug is in the patient’s body while immunotherapy agents cause modifications in the checkpoints of the immune system that may be permanent.

      Because the immune system is altered during treatment with immunotherapy agents, Burke says the severity of immunotherapy-related adverse events can be much worse than chemotherapy-related adverse events. Also, it is difficult to predict which patients will experience severe adverse events from immunotherapy treatment.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with blond wavy hair in front of a dark blue background
      Photo of a man wearing a suit with a bowtie in front of an Oncology Nursing News backdrop
      2 experts are featured in this series.
      Related Content

      Image of a bladder

      Intravesical Mitomycin Produces 24-Month Response in Recurrent NMIBC

      Jax DiEugenio
      August 19th 2025
      Article

      The Vitals Podcast

      Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

      Lindsay Fischer
      August 19th 2025
      Podcast

      Graphic of a kidney

      Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

      Ashling Wahner
      August 19th 2025
      Article

      the vitals

      Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

      Lindsay Fischer
      August 19th 2025
      Podcast

      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      August 19th 2025
      Article

      Line illustration of the male genitourinary tract

      Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

      Bridget Hoyt
      August 19th 2025
      Article
      Related Content

      Image of a bladder

      Intravesical Mitomycin Produces 24-Month Response in Recurrent NMIBC

      Jax DiEugenio
      August 19th 2025
      Article

      The Vitals Podcast

      Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

      Lindsay Fischer
      August 19th 2025
      Podcast

      Graphic of a kidney

      Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

      Ashling Wahner
      August 19th 2025
      Article

      the vitals

      Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

      Lindsay Fischer
      August 19th 2025
      Podcast

      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      August 19th 2025
      Article

      Line illustration of the male genitourinary tract

      Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

      Bridget Hoyt
      August 19th 2025
      Article

      Latest Conference Coverage

      Personalized Cancer Vaccines: Watching For Immune-Related, Vaccine AEs

      Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

      PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.